16.32
-0.56 (-3.32%)
| Previous Close | 16.88 |
| Open | 16.79 |
| Volume | 2,312,156 |
| Avg. Volume (3M) | 2,391,325 |
| Market Cap | 1,641,090,176 |
| Price / Sales | 25.30 |
| Price / Book | 2.68 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -332.71% |
| Diluted EPS (TTM) | -4.58 |
| Quarterly Revenue Growth (YOY) | -90.50% |
| Total Debt/Equity (MRQ) | 22.01% |
| Current Ratio (MRQ) | 4.82 |
| Operating Cash Flow (TTM) | -347.25 M |
| Levered Free Cash Flow (TTM) | -156.52 M |
| Return on Assets (TTM) | -20.26% |
| Return on Equity (TTM) | -43.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Beam Therapeutics Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 2.25 |
|
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.27% |
| % Held by Institutions | 78.73% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Arch Venture Management, Llc | 31 Mar 2025 | 4,540,132 |
| Mwg Management Ltd. | 31 Mar 2025 | 2,266,934 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 80.00 (HC Wainwright & Co., 390.20%) | Buy |
| Median | 42.00 (157.35%) | |
| Low | 25.00 (Barclays, 53.19%) | Hold |
| Average | 49.43 (202.88%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 19.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 07 May 2025 | 25.00 (53.19%) | Hold | 16.23 |
| Guggenheim | 07 May 2025 | 55.00 (237.01%) | Buy | 16.23 |
| Wells Fargo | 07 May 2025 | 70.00 (328.92%) | Buy | 16.23 |
| HC Wainwright & Co. | 07 Apr 2025 | 80.00 (390.20%) | Buy | 15.30 |
| 10 Mar 2025 | 80.00 (390.20%) | Buy | 25.69 | |
| B of A Securities | 28 Mar 2025 | 42.00 (157.35%) | Buy | 22.21 |
| Jones Trading | 10 Mar 2025 | 34.00 (108.33%) | Buy | 25.69 |
| Scotiabank | 10 Mar 2025 | 40.00 (145.10%) | Buy | 25.69 |
| 03 Mar 2025 | 25.00 (53.19%) | Hold | 25.10 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |